| Sleep Apnea, Obstructive
Sunosi vs Zepbound
Side-by-side clinical, coverage, and cost comparison for sleep apnea, obstructive.Deep comparison between: Sunosi vs Zepbound with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZepbound has a higher rate of injection site reactions vs Sunosi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zepbound but not Sunosi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Sunosi
Zepbound
At A Glance
Oral
Once daily
DNRI
SC injection
Once weekly
GIP/GLP-1 receptor agonist
Indications
- Narcolepsy
- Sleep Apnea, Obstructive
- Obesity
- Sleep Apnea, Obstructive
Dosing
Narcolepsy 75 mg orally once daily upon awakening; may double every 3 days based on efficacy and tolerability; maximum 150 mg once daily.
Sleep Apnea, Obstructive 37.5 mg orally once daily upon awakening; may double every 3 days based on efficacy and tolerability; maximum 150 mg once daily.
Renal Impairment Moderate (eGFR 30-59 mL/min/1.73 m2): start 37.5 mg once daily, may increase to max 75 mg after at least 7 days. Severe (eGFR 15-29 mL/min/1.73 m2): 37.5 mg once daily; maximum 37.5 mg. ESRD: not recommended.
Obesity Starting dose 2.5 mg SC once weekly for 4 weeks, escalating in 2.5 mg increments every 4 weeks; maintenance 5 mg, 10 mg, or 15 mg SC once weekly.
Sleep Apnea, Obstructive Starting dose 2.5 mg SC once weekly for 4 weeks, escalating in 2.5 mg increments every 4 weeks; maintenance 10 mg or 15 mg SC once weekly.
Contraindications
- Concomitant use with MAO inhibitors or within 14 days after discontinuing MAOI treatment due to risk of hypertensive reaction
- Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Known serious hypersensitivity to tirzepatide or any excipient in ZEPBOUND
Adverse Reactions
Most common (>=5%) headache, nausea, decreased appetite, anxiety, insomnia
Serious blood pressure and heart rate increases, psychiatric symptoms
Postmarketing hypersensitivity reactions (rash erythematous, rash, urticaria)
Most common (>=2%) Nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, gastroesophageal reflux disease, flatulence, abdominal distension, dizziness
Serious Risk of thyroid C-cell tumors, severe gastrointestinal reactions, acute kidney injury, acute gallbladder disease, acute pancreatitis, hypersensitivity reactions including anaphylaxis and angioedema, hypoglycemia, diabetic retinopathy complications, pulmonary aspiration
Postmarketing Acute pancreatitis, hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation including fecal impaction, anaphylaxis, angioedema, pulmonary aspiration, acute renal failure or worsening of chronic renal failure
Pharmacology
Solriamfetol is a dopamine and norepinephrine reuptake inhibitor (DNRI) that inhibits reuptake of dopamine and norepinephrine with no appreciable binding to serotonin transporters or to dopamine, serotonin, norepinephrine, GABA, adenosine, histamine, orexin, or acetylcholine receptors.
Tirzepatide is a dual GIP receptor and GLP-1 receptor agonist that selectively binds and activates both receptors, reducing body weight by decreasing caloric intake and affecting appetite regulation, stimulating glucose-dependent insulin secretion, reducing glucagon secretion, and delaying gastric emptying.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Sunosi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (1/12)
Zepbound
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Sunosi
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (6/8) · Qty limit (7/8)
Zepbound
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (1/8)
Humana
Sunosi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Zepbound
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Narcolepsy
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$25/fillfill
Zepbound Savings Card - Covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SunosiView full Sunosi profile
ZepboundView full Zepbound profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.